1,25(OH) 2 D 3 attenuates sleep disturbance in mouse models of Lewis lung cancer, in silico and in vivo

2021 ◽  
Author(s):  
Min Ai ◽  
Shuang‐shuang Li ◽  
Hong Chen ◽  
Xi‐ting Wang ◽  
Jiang‐nan Sun ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Sleep Disturbance ◽  
Mouse Models ◽  
In Silico ◽  
Lewis Lung ◽  
Lewis Lung Cancer

scholarly journals The in vivo study on the radiobiologic effect of prolonged delivery time to tumor control in C57BL mice implanted with Lewis lung cancer

2011 ◽  
Vol 6 (1) ◽  
pp. 4 ◽  
Author(s):  
Xin Wang ◽  
Xiao-Peng Xiong ◽  
Jiade Lu ◽  
Guo-Pei Zhu ◽  
Shao-Qin He ◽  
...  
Keyword(s):  
Lung Cancer ◽  
In Vivo Study ◽  
Tumor Control ◽  
Delivery Time ◽  
Lewis Lung ◽  
Lewis Lung Cancer ◽  
C57bl Mice

In vivo Anti-tumor Effect of siRNA Against STAT3 on Transplanted Lewis Lung Cancer in Mice

2008 ◽  
Vol 24 (3) ◽  
pp. 330-337 ◽  
Author(s):  
C WANG ◽  
R WANG ◽  
M SUN ◽  
J LI ◽  
N GAO ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lewis Lung ◽  
Lewis Lung Cancer

scholarly journals Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models

2018 ◽  
Vol Volume 11 ◽  
pp. 5133-5142 ◽  
Author(s):  
Xibing Zhuang ◽  
Tiankui Qiao ◽  
Sujuan Yuan ◽  
Qi Zhang ◽  
Wei Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lewis Lung ◽  
Lewis Lung Cancer ◽  
Antitumor Effects ◽  
Cancer Models

scholarly journals Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis

2020 ◽  
Vol 39 (1) ◽  
Author(s):  
Ze-Bo Jiang ◽  
Ju-Min Huang ◽  
Ya-Jia Xie ◽  
Yi- Zhong Zhang ◽  
Chan Chang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Lewis Lung Carcinoma ◽  
Small Cell ◽  
Lewis Lung ◽  
Small Cell Lung ◽  
Programmed Death ◽  
Lewis Lung Carcinoma Model ◽  
Anti Tumor Activity

Abstract Background Accumulating evidence showed that regulating tumor microenvironment plays a vital role in improving antitumor efficiency. Programmed Death Ligand 1 (PD-L1) is expressed in many cancer cell types, while its binding partner Programmed Death 1 (PD1) is expressed in activated T cells and antigen-presenting cells. Whereas, its dysregulation in the microenvironment is poorly understood. In the present study, we confirmed that evodiamine downregulates MUC1-C, resulting in modulating PD-L1 expression in non-small cell lung cancer (NSCLC). Methods Cell viability was measured by MTT assays. Apoptosis, cell cycle and surface PD-L1 expression on NSCLC cells were analyzed by flow cytometry. The expression of MUC1-C and PD-L1 mRNA was measured by real time RT-PCR methods. Protein expression was examined in evodiamine-treated NSCLC cells using immunoblotting or immunofluorescence assays. The effects of evodiamine treatment on NSCLC sensitivity towards T cells were investigated using human peripheral blood mononuclear cells and Jurkat, apoptosis and IL-2 secretion assays. Female H1975 xenograft nude mice were used to assess the effect of evodiamine on tumorigenesis in vivo. Lewis lung carcinoma model was used to investigate the therapeutic effects of combination evodiamine and anti-PD-1 treatment. Results We showed that evodiamine significantly inhibited growth, induced apoptosis and cell cycle arrest at G2 phase of NSCLC cells. Evodiamine suppressed IFN-γ-induced PD-L1 expression in H1975 and H1650. MUC1-C mRNA and protein expression were decreased by evodiamine in NSCLC cells as well. Evodiamine could downregulate the PD-L1 expression and diminish the apoptosis of T cells. It inhibited MUC1-C expression and potentiated CD8+ T cell effector function. Meanwhile, evodiamine showed good anti-tumor activity in H1975 tumor xenograft, which reduced tumor size. Evodiamine exhibited anti-tumor activity by elevation of CD8+ T cells in vivo in Lewis lung carcinoma model. Combination evodiamine and anti-PD-1 mAb treatment enhanced tumor growth control and survival of mice. Conclusions Evodiamine can suppress NSCLC by elevating of CD8+ T cells and downregulating of the MUC1-C/PD-L1 axis. Our findings uncover a novel mechanism of action of evodiamine and indicate that evodiamine represents a potential targeted agent suitable to be combined with immunotherapeutic approaches to treat NSCLC cancer patients. MUC1-C overexpression is common in female, non-smoker, patients with advanced-stage adenocarcinoma.

Sign in / Sign up

Export Citation Format

Share Document